Association between H-type arterial hypertension and vascular stiffness (a pilot study)

Authors

DOI:

https://doi.org/10.14739/2310-1210.2021.1.224862

Keywords:

homocysteine, hypertension, arterial stiffness

Abstract

Increased arterial stiffness is an important determinant of cardiovascular risk. Elevated total homocysteine (HC) levels appeared to be an independent risk factor for cardiovascular disease (CVD). To date, clinical studies on the relationship between HC and pulse wave velocity (PWV) assessment have shown conflicting results.

Aim. To estimate the prevalence of hyperhomocystinemia (HHc) among patients with mild to moderate arterial hypertension and the effect of HHc on the vascular wall stiffness.

Materials and methods. Our study was carried out as a part of the HYPSTER study in Ukraine. The study included 40 patients with I and II degree of arterial hypertension (AH) (average office systolic blood pressure (SBP)/diastolic (DBP) – 155.88/92.60 ± 1.63/1.43 mm Hg), heart rate – 71.40 ± 1.29 beats/min. The average age of the patients was 55.85 ± 2.09 (26–74) years. Patients with HC levels ≥10 μmol/l were defined as patients with H-type AH (HHc). Arterial stiffness was determined by PWV.

Results. We found that at the beginning of the study, 75 % (30 patients with mild and moderate hypertension) had H-type hypertension with an increased level of HC. Patients with H-type AH and AH patients without HHc did not differ in age and AH duration. At the same time, patients with H-type AH had higher body weights and BMI. Office SBP in patients with H-type hypertension was higher compared to patients without HHc (156.45 ± 1.04 mm Hg vs. 152.55 ± 1.41 mm Hg at the beginning (P < 0.05) and 130.65 ± 0.96 mm Hg vs. 126.97 ± 1.08 mm Hg after 6 months (P < 0.05)) of treatment, respectively. BMI in H-type AH was 30.72 ± 0,39 kg/m2 vs. 28.34 ± 0.69 kg/m2 without HHc (P < 0.05) at the beginning of the study. It was difficult to achieve target levels of BP in the patients with H-type hypertension during the treatment and they had high initial blood pressure values. In contrast to the patients without HHc, H-type AH patients had a more pronounced degree of insulin resistance (according to the HOMA index), lower GFR both at the beginning and at the end of the treatment. According to ambulatory BP monitoring, H-type AH patients presented with a significantly higher SBP level before starting the treatment compared to those with AH without HHc. The regression analysis revealed an association between HC and PWVel, regardless of the degree of BP reduction (PWVel (6 months), m/s, β = 0.307, P = 0.001).

Conclusions. Hyperhomocystinemia was observed in 75 % of patients with arterial hypertension. Homocysteine levels were associated with vascular stiffness, regardless of the reduction in blood pressure level.

References

Yingchoncharoen, T., Limpijankit, T., Jongjirasiri, S., Laothamatas, J., Yamwong, S., & Sritara, P. (2012). Arterial stiffness contributes to coronary artery disease risk prediction beyond the traditional risk score (RAMA-EGAT score). Heart Asia, 4(1), 77-82. https://doi.org/10.1136/heartasia-2011-010079

Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D. E., Jaarsma, T., Kirchhof, P., Kjeldsen, S. E., Laurent, S., Manolis, A. J., Nilsson, P. M., Ruilope, L. M., Schmieder, R. E., … Wood, D. A. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34(28), 2159-2219. https://doi.org/10.1093/eurheartj/eht151

Franklin, S. S., Larson, M. G., Khan, S. A., Wong, N. D., Leip, E. P., Kannel, W. B., & Levy, D. (2001). Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging? Circulation, 103(9), 1245-1249. https://doi.org/10.1161/01.cir.103.9.1245

Wald, D. S., Law, M., & Morris, J. K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325(7374), Article 1202. https://doi.org/10.1136/bmj.325.7374.1202

de Bree, A., Mennen, L. I., Zureik, M., Ducros, V., Guilland, J. C., Nicolas, J. P., Emery-Fillon, N., Blacher, J., Hercberg, S., & Galan, P. (2006). Homocysteine is not associated with arterial thickness and stiffness in healthy middle-aged French volunteers. International Journal of Cardiology, 113(3), 332-340. https://doi.org/10.1016/j.ijcard.2005.11.045

Vyssoulis, G., Karpanou, E., Kyvelou, S. M., Adamopoulos, D., Gialernios, T., Gymnopoulou, E., Cokkinos, D., & Stefanadis, C. (2010). Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls. Journal of Human Hypertension, 24(3), 183-189. https://doi.org/10.1038/jhh.2009.50

Xiao, W., Bai, Y., Ye, P., Luo, L., Liu, D., Wu, H., & Bai, J. (2014). Plasma Homocysteine Is Associated with Aortic Arterial Stiffness but not Wave Reflection in Chinese Hypertensive Subjects. PLOS ONE, 9(1), Article e85938. https://doi.org/10.1371/journal.pone.0085938

Zhang, Q., Qiu, D. X., Fu, R. L., Xu, T. F., Jing, M. J., Zhang, H. S., Geng, H. H., Zheng, L. C., & Wang, P. X. (2016). H-Type Hypertension and C Reactive Protein in Recurrence of Ischemic Stroke. International Journal of Environmental Research and Public Health, 13(5), Article 477. https://doi.org/10.3390/ijerph13050477

Sirenko, Yu. M., Rekovets, O. L., Svischenko, E. P., Ena, L. M., Torbas, E. A., Kushnir, S. M., Gulkevych, O. V., & Mudruk, I. V. (2017). Vidkryte klinichne doslidzhennia antyhipertenzyvnoi efektyvnosti henerychnoho preparatu telmisartan (KhIPotel) abo kombinatsii iz S-amlodypinom (Semlopin) chy hidrokhlortiazydom u TERapii patsiientiv iz miakoiu ta pomirnoiu arterialnoiu hipertenziieiu (rezultaty doslidzhennia KhIPSTER-AH) [Open clinical study of antihypertensive efficacy of generic drug telmisartan (hYPotel) or a combination with S-amlodipine (Semlopin) or hydrochlorothiazide in the therapy of patients with mild to moderate arterial hypertension (AH) (results of the HIPSTER-AH study)]. Arterialna hipertenziia, (1), 11-23. https://doi.org/10.22141/2224-1485.1.51.2017.96247 [in Ukrainian].

Sirenko, Yu. M., Rekovets, O. L., Svischenko, E. P., Ena, L. M., Torbas, E. A., Kushnir, S. M., Gulkevych, O. V., & Mudruk, I. V. (2017). Metabolichni efekty henerychnoho preparatu telmisartan (KhIPotel) abo yoho kombinatsii z S-amlodypinom (Semlopin) chy hidrokhlortiazydom u TERapii patsiientiv iz m’iakoiu ta pomirnoiu arterialnoiu hipertenziieiu (rezultaty doslidzhennia KhIPSTER-AH) [Metabolic effects of the generic drug telmisartan (HYPotel) or its combination with S-amlodipine (Samlopin) or hydrochlorothiazide in the ThERapy of patients with mild to moderate arterial hypertension (results of the HYPSTER-AH study)]. Arterialna hipertenziia, (2), 69-83. https://doi.org/10.22141/2224-1485.2.52.2017.101296 [in Ukrainian].

Sen, U., Mishra, P. K., Tyagi, N., & Tyagi, S. C. (2010). Homocysteine to hydrogen sulfide or hypertension. Cell Biochemistry and Biophysics, 57(2-3), 49-58. https://doi.org/10.1007/s12013-010-9079-y

Zhang, W., Sun, K., Chen, J., Liao, Y., Qin, Q., Ma, A., Wang, D., Zhu, Z., Wang, Y., & Hui, R. (2009). High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clinical Science, 118(3), 187-194. https://doi.org/10.1042/CS20090142

Xu, G., Liu, X., Wu, W., Zhang, R., & Yin, Q. (2007). Recurrence after Ischemic Stroke in Chinese Patients: Impact of Uncontrolled Modifiable Risk Factors. Cerebrovascular Diseases, 23(2-3), 117-120. https://doi.org/10.1159/000097047

Aiyagari, V., & Badruddin, A. (2009). Management of hypertension in acute stroke. Expert Review of Cardiovascular Therapy, 7(6), 637-646. https://doi.org/10.1586/erc.09.45

Saposnik, G., Ray, J. G., Sheridan, P., McQueen, M., Lonn, E., & Heart Outcomes Prevention Evaluation 2 Investigators. (2009). Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability. Stroke, 40(4), 1365-1372. https://doi.org/10.1161/strokeaha.108.529503

Leoo, T., Lindgren, A., Petersson, J., & von Arbin, M. (2008). Risk Factors and Treatment at Recurrent Stroke Onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovascular Diseases, 25(3), 254-260. https://doi.org/10.1159/000113864

Graham, I. M., Daly, L. E., Refsum, H. M., Robinson, K., Brattström, L. E., Ueland, P. M., Palma-Reis, R. J., Boers, G. H., Sheahan, R. G., Israelsson, B., Uiterwaal, C. S., Meleady, R., McMaster, D., Verhoef, P., Witteman, J., Rubba, P., Bellet, H., Wautrecht, J. C., de Valk, H. W., Sales Lúis, A. C., … Andria, G. (1997). Plasma Homocysteine as a Risk Factor for Vascular Disease. The European Concerted Action Project. JAMA, 277(22), 1775-1781. https://doi.org/10.1001/jama.1997.03540460039030

Zhou, F., Hou, D., Wang, Y., & Yu, D. (2020). Evaluation of H-type hypertension prevalence and its influence on the risk of increased carotid intima-media thickness among a high-risk stroke population in Hainan Province, China. Medicine, 99(35), Article e21953. https://doi.org/10.1097/MD.0000000000021953

Qin, X., & Huo, Y. (2016). H-Type hypertension, stroke and diabetes in China: Opportunities for primary prevention. Journal of Diabetes, 8(1), 38-40. https://doi.org/10.1111/1753-0407.12333

Towfighi, A., Markovic, D., & Ovbiagele, B. (2010). Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. Journal of the Neurological Sciences, 298(1-2), 153-157. https://doi.org/10.1016/j.jns.2010.07.013

Zhang, J., Liu, Y., Wang, A., Wang, D., Jiang, R., Jia, J., Chen, S., & Zhao, X. (2018). Association between H-type Hypertension and Asymptomatic Extracranial Artery Stenosis. Scientific Reports, 8(1), Article 1328. https://doi.org/10.1038/s41598-018-19740-0

Qian, G., Zeng, L. H., Liu, Y. Q., Cao, F., Chen, Y. D., Zheng, M. L., Yang, X. C., Xu, X. P., & Huo, Y. (2015). Associations between plasma total homocysteine, blood pressure stages and pulse wave velocity in Chinese rural community population. Blood Pressure, 24(6), 340-346. https://doi.org/10.3109/08037051.2014.997089

Chen, L., Wang, B., Wang, J., Ban, Q., Wu, H., Song, Y., Zhang, J., Cao, J., Zhou, Z., Liu, L., Cao, T., Gao, L., Guo, H., Zhang, T., Tang, G., Huang, X., Zhang, Y., Li, J., Huo, Y., Cheng, X., … Qin, X. (2018). Association between serum total homocysteine and arterial stiffness in adults: a community-based study. Journal of Clinical Hypertension, 20(4), 686-693. https://doi.org/10.1111/jch.13246

Zhang, S., Bai, Y. Y., Luo, L. M., Xiao, W. K., Wu, H. M., & Ye, P. (2014). Association between serum homocysteine and arterial stiffness in elderly: a community-based study. Journal of Geriatric Cardiology, 11(1), 32-38. https://doi.org/10.3969/j.issn.1671-5411.2014.01.007

Wang, K., Wang, Y., Chu, C., Hu, J., Zheng, W., Yan, Y., Ma, Q., Gao, K., Yuan, Y., & Mu, J. (2019). Joint Association of Serum Homocysteine and High-Sensitivity C-Reactive Protein with Arterial Stiffness in Chinese Population: A 12-Year Longitudinal Study. Cardiology, 144(1-2), 27-35. https://doi.org/10.1159/000501742

Published

2021-04-07

How to Cite

1.
Sirenko YM, Rekovets OL, Torbas OO, Kushnir SM, Sirenko OY. Association between H-type arterial hypertension and vascular stiffness (a pilot study) . Zaporozhye Medical Journal [Internet]. 2021Apr.7 [cited 2024Jul.20];23(1):32-41. Available from: http://zmj.zsmu.edu.ua/article/view/224862

Issue

Section

Original research